Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 7/20 | 0.55 |
| ▸ | APP | P05067 | 8/20 | 0.54 |
| ▸ | NPC1 | O15118 | 3/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30065009 | 0.85 | MAOB (0.57) | MAOBRAB9ASMN1; SMN2MAOA | |
| SCHEMBL8251097 | 0.85 | MAOB (0.57) | MAOBRAB9ASMN1; SMN2MAOA | |
| SCHEMBL14700006 | 0.84 | APP (0.47) | MAOBAPPNPC1RAB9APOLB | |
| SCHEMBL29468641 | 0.82 | SMN1; SMN2 (0.46) | MAOBPOLBSMN1; SMN2MAOA | |
| SCHEMBL3900531 | 0.81 | LTA4H (0.52) | MAOBNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL25173929 | 0.80 | MAOB (0.55) | MAOBAPPNPC1RAB9ATDP1 | |
| SCHEMBL1042775 | 0.80 | CA12 (0.46) | — | |
| SCHEMBL30180094 | 0.80 | CA12 (0.46) | — | |
| SCHEMBL16769862 | 0.80 | RXRA (0.39) | MAOBMAOA | |
| SCHEMBL14541925 | 0.79 | MAOB (0.65) | MAOBAPPNPC1RAB9APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9943519-B2 | Pharmaceutical compounds | GENENTECH, INC. (US) | 2018-04-17 | — | — | US | disclosed |
| EP-2938615-B1 | IMIDAZOPYRIDAZINE DERIVATIVES AS GABAA RECEPTOR MODULATORS | PFIZER LTD (GB) | 2016-10-26 | — | — | EP | disclosed |
| US-20160152632-A9 | PHARMACEUTICAL COMPOUNDS | PIRAMED LIMITED (GB) | 2016-06-02 | — | — | US | disclosed |
| EP-2938615-A1 | IMIDAZOPYRIDAZINE DERIVATIVES AS GABAA RECEPTOR MODULATORS | Pfizer Limited (GB) | 2015-11-04 | — | — | EP | disclosed |
| US-20150259352-A1 | Chemical Compounds | PFIZER LTD (GB) | 2015-09-17 | — | — | US | disclosed |
| US-20150105396-A1 | Chemical Compounds | PFIZER LTD (GB) | 2015-04-16 | — | — | US | disclosed |
| US-8952008-B2 | Chemical compounds | PFIZER LIMITED (GB) | 2015-02-10 | — | — | US | disclosed |
| US-20140309216-A1 | PHARMACEUTICAL COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2014-10-16 | — | — | US | disclosed |
| US-8802670-B2 | Pharmaceutical compounds | F. HOFFMANN-LA ROCHE AG (CH) | 2014-08-12 | — | — | US | disclosed |
| US-20140171435-A1 | Chemical Compounds | PFIZER LIMITED (GB) | 2014-06-19 | — | — | US | disclosed |
| WO-2014091368-A1 | IMIDAZOPYRIDAZINE DERIVATIVES AS GABAA RECEPTOR MODULATORS | PFIZER LIMITED (GB) | 2014-06-19 | — | — | WO | disclosed |
| EP-2402347-A1 | Pharmaceutical compounds | F. Hoffmann-La Roche AG (CH) | 2012-01-04 | — | — | EP | disclosed |
| EP-2041139-B1 | PHARMACEUTICAL COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2011-11-09 | — | — | EP | disclosed |
| EP-2041139-A2 | PHARMACEUTICAL COMPOUNDS | F.HOFFMANN-LA ROCHE AG (CH) | 2009-04-01 | — | — | EP | disclosed |
| US-20080076758-A1 | 1S,4S)-2-((2-(1H-indazol-4-yl)-4- morpholinothieno[3,2-d]pyrirnidin-6- yl)methyl)-5-methylsulfonyl-2,5- diaza-bicyclo[2.2.1]heptane; 2-(6-fluoropyridin-3-yl)-6-((4- methylsulfonylpiperazin-1-yl)methyl)-4- morpholinothieno[3,2-d]pyrimidine; treats cancer mediated by pik3 kinase; enzyme inhibitors | PIRAMED LIMITED (GB) | 2008-03-27 | — | — | US | disclosed |
| WO-2007127175-A2 | PHARMACEUTICAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150259352-A1 | Chemical Compounds | GABRA5, GABRA4, GABRA3 | MAOB 730/4885APP 3821/4885NPC1 2033/4885 |
| US-20080076758-A1 | 1S,4S)-2-((2-(1H-indazol-4-yl)-4- morpholinothieno[3,2-d]pyrirnidin-6- yl)methyl)-5-methylsulfonyl-2,5- diaza-bicyclo[2.2.1]heptane; 2-(6-fluoropyridin-3-yl)-6-((4- methylsulfonylpiperazin-1-yl)methyl)-4- morpholinothieno[3,2-d]pyrimidine; treats cancer mediated by pik3 kinase; enzyme inhibitors | PIK3CA, PIK3CD, PIK3CB | MAOB 4312/4885APP 4114/4885NPC1 1789/4885 |
| US-20150105396-A1 | Chemical Compounds | GABRA5, GABRA4, GABRA3 | MAOB 730/4885APP 3821/4885NPC1 2033/4885 |
| US-20140309216-A1 | PHARMACEUTICAL COMPOUNDS | PIK3CA, PIK3CD, AKT3 | MAOB 2218/4885APP 2141/4885NPC1 250/4885 |
| US-20140171435-A1 | Chemical Compounds | GABRA5, GABRA4, GABRA3 | MAOB 730/4885APP 3821/4885NPC1 2033/4885 |
| US-20160152632-A9 | PHARMACEUTICAL COMPOUNDS | PIK3CA, PIK3CD, AKT3 | MAOB 2218/4885APP 2141/4885NPC1 250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.